Table 4

Unadjusted and adjusted analyses of impact of mesalamine/sulfasalazine on risk of severe COVID-19

Dose comparisonOR (95% CI)aOR (95% CI)P value*P value†Total n in modelN with severe COVID-19
Mesalamine/sulfasalazine
(ref=no mesalamine/sulfasalazine)
2.43 (1.90 to 3.11)1.70 (1.26 to 2.29)<0.001<0.0061415111
Mesalamine/sulfasalazine monotherapy4.51 (2.68 to 7.61)3.52 (1.93 to 6.45)<0.001<0.00690374
mesalamine/sulfasalazine and TNF antagonist
(ref=TNF antagonist monotherapy)§
2.79 (1.07 to 7.22)2.34 (0.86 to 6.37)0.100.455
High dose mesalamine/sulfasalazine
(ref=low dose)
1.07 (0.67 to 1.72)0.99 (0.63 to 1.57)0.991.0041056
  • *P value for adjusted model.

  • †Adjusted p value using Bonferroni correction method for six hypothesis tests that were conducted.

  • ‡Model adjusted for age, sex, race (black vs non-Hispanic white, Asian vs non-Hispanic white), Hispanic versus non-Hispanic, disease type, disease activity, cardiovascular disease, corticosteroids, TNF antagonist, thiopurine, diabetes, lung disease and cancer.

  • §Model adjusted for age, sex, race (Asian vs non-Asian), disease type, disease activity, cardiovascular disease and corticosteroids.

  • ¶Model adjusted for age, sex, race (white vs non-white), disease type, disease activity, cardiovascular disease, corticosteroids, combination therapy and thiopurine monotherapy.

  • aOR, adjusted OR; TNF, tumour necrosis factor.